$A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1)$

A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1)

Inotuzumab ozogamicin (InO) is a CD22-directed antibody conjugated with calicheamicin approved for adult relapsed or refractory CD22-positive acute lymphoblastic leukemia (ALL). This phase 1 study primarily aimed to determine the pediatric recommended doses of InO through the standard 3 + 3 design,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of hematology 2022-10, Vol.116 (4), p.612-621
Hauptverfasser:	Nakayama, Hideki, Ogawa, Chitose, Sekimizu, Masahiro, Fujisaki, Hiroyuki, Kosaka, Yoshiyuki, Hashimoto, Hiroya, Saito, Akiko M., Horibe, Keizo
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute lymphoblastic leukemia Adolescent Adults Alanine Alanine Transaminase Antibodies Anticancer properties Aspartate aminotransferase Aspartate Aminotransferases Blood cells Calicheamicin Calicheamicins CD22 antigen Child Child, Preschool Design standards Effectiveness Hematology Humans Immunogenicity Inotuzumab Ozogamicin Japan Leukemia Liver diseases Lymphatic leukemia Medicine Medicine & Public Health Minimal residual disease Monoclonal antibodies Oncology Original Article Pediatrics Pharmacokinetics Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Remission Sialic Acid Binding Ig-like Lectin 2 - therapeutic use Targeted cancer therapy Toxicity Transaminases Veno-occlusive disease
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!